Overview

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to determine the effect of ranolazine when added to metformin on glycemic control in adults with type 2 diabetes mellitus (T2DM) who are inadequately controlled despite current treatment with stable metformin therapy in addition to diet and exercise.
Phase:
Phase 3
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Metformin
Ranolazine